Register entry
- Registered sites
- 0
- Active NDC listings
- 10
- Labeller names
- 2
- Live patents
- 24
- Exclusivities
- 1
- Countries
- 0
Catalogue
Drug listings by form and route
1010 active NDC listings: 10 human prescription drug. By marketing category: BLA 6, NDA 4.
| Dosage form | NDCs |
|---|---|
| capsule, delayed release | 6 |
| capsule, extended release | 4 |
| Route | NDCs |
|---|---|
| oral | 10 |
| Labeller name on the listing | NDCs |
|---|---|
| vivus llc | 6 |
| vivus llc | 4 |
Exclusivity
Patents and exclusivities
24| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8895057 | QSYMIAphentermine hydrochloride; topiramate | use | Jun 2028 |
| 8895058 | QSYMIAphentermine hydrochloride; topiramate | product | Jun 2028 |
| 9011905 | QSYMIAphentermine hydrochloride; topiramate | product | Jun 2028 |
| 9011906 | QSYMIAphentermine hydrochloride; topiramate | use | Jun 2028 |
| 8580298 | QSYMIAphentermine hydrochloride; topiramate | product | May 2029 |
| 8580299 | QSYMIAphentermine hydrochloride; topiramate | use | Jun 2029 |
| Product | Exclusivity | Until |
|---|---|---|
| QSYMIAPHENTERMINE HYDROCHLORIDE; TOPIRAMATE | M-308 Miscellaneous | Sept 2027 |
Catalogue
Marketed products
10| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| PANCREAZE | PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE | capsule, delayed release, oral | 62541-401BLA |
| PANCREAZE | PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE | capsule, delayed release, oral | 62541-402BLA |
| PANCREAZE | PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE | capsule, delayed release, oral | 62541-403BLA |
| PANCREAZE | PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE | capsule, delayed release, oral | 62541-404BLA |
| PANCREAZE | PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE | capsule, delayed release, oral | 62541-405BLA |
| PANCREAZE | PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, and PANCRELIPASE PROTEASE | capsule, delayed release, oral | 62541-406BLA |
| Qsymia | phentermine and topiramate | capsule, extended release, oral | 62541-201NDA |
| Qsymia | phentermine and topiramate | capsule, extended release, oral | 62541-202NDA |
| Qsymia | phentermine and topiramate | capsule, extended release, oral | 62541-203NDA |
| Qsymia | phentermine and topiramate | capsule, extended release, oral | 62541-204NDA |
Enquiry
Common questions
- Is Vivus LLC FDA approved?
- Vivus LLC holds no registered establishment of its own; 10 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Vivus LLC make?
- 10 products are listed under Vivus LLC in the openFDA NDC Directory, most often as capsule, delayed release; capsule, extended release. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.